Clobutinol

Summary

Clobutinol (CHEMBL1474889) is an approved small molecule (ATC R05DB03); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05DB03
• Indications: 1 condition
• Chemistry: 255.78 Da · C14H22ClNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1474889
Name	Clobutinol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	26937
ATC	R05DB03
Molecular formula	C14H22ClNO
Molecular weight	255.78
InChIKey	KVHHQGIIZCJATJ-UHFFFAOYSA-N

SMILES: CC(CN(C)C)C(C)(CC1=CC=C(C=C1)Cl)O

IUPAC name: 1-(4-chlorophenyl)-4-(dimethylamino)-2,3-dimethylbutan-2-ol

Also known as: Clobutinol, Iversal, KAT 256 FREE BASE, KAT-256 FREE BASE, R05DB03, SID29215379, CLOBUTINOL, clobutinol

Parent form; salt/anhydrous children: CHEMBL3183114

Patent coverage: 341 distinct patent families (1,210 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C, Sodium-dependent serotonin transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ALDH1A1	6.82	Potency	149.9	nM	CHEMBL_ACT_4185560
KCNH2	5.07	AC50	8453	nM	CHEMBL_ACT_25118116

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).